LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial

• Main Authors: Talia Golan (Author), Ravit Geva (Author), Donald Richards (Author), Srinivasan Madhusudan (Author), Boris Kin Lin (Author), Haofei Tiffany Wang (Author), Richard A. Walgren (Author), Salomon M. Stemmer (Author)
• Format: Book
• Published: Wiley, 2018-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Cachexia is a formidable clinical challenge in pancreatic cancer. We assessed LY2495655 (antimyostatin antibody) plus standard‐of‐care chemotherapy in pancreatic cancer using cachexia status as a stratifier. Methods In this randomized, phase 2 trial, patients with stage II-IV pan...